



Product Information

Product ID B184761

CAS No. 1799711-21-9

Chemical Name

Synonym

Formula $C_{38}H_{37}ClN_8O_7S$

Formula Wt. 785.3

Melting Point


Purity $\geq 98\%$

Solubility

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description dBET1 is a bifunctional PROTAC (Proteolysis Targeting Chimera) that links JQ1, a BET bromodomain ligand, to a thalidomide-based CRBN (cereblon) E3 ligase recruiter. Upon cell entry, dBET1 simultaneously engages BET bromodomain proteins (BRD2, BRD3, BRD4) and CRBN, forming a ternary complex that drives polyubiquitination and proteasomal degradation of BET proteins within hours. dBET1 is a benchmark tool compound in targeted protein degradation research for studying BET protein biology and gene regulation.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
B184761	1 mg	\$55.00
B184761	5 mg	\$185.00
B184761	25 mg	\$525.00

- References**
1. Winter GE, Buckley DL, Paulk J, et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. *Science*. 2015;348(6241):1376-81. PMID: 25999370.
 2. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. *Nature*. 2010;468(7327):1067-73. PMID: 20871596.
 3. Cromm PM, Crews CM. Targeted Protein Degradation: from Chemical Biology to Drug Discovery. *Cell Chem Biol*. 2017;24(9):1181-1190. PMID: 28938091.
 4. Zengerle M, Chan KH, Ciulli A. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. *ACS Chem Biol*. 2015;10(8):1770-7. PMID: 26035625.
 5. Bondeson DP, Mares A, Smith IE, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. *Nat Chem Biol*. 2015;11(8):611-7. PMID: 26066762.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.